In a cohort study of adults with type 2 diabetes, initiation of GLP-1 therapy was associated with a reduced 3- to 5-year risk of obesity-related cancers, but only relative to insulin or sulfonylureas. There was no significant difference in comparison with metformin or other diabetes medications.
These patterns, the study authors wrote, “may reflect both treatment selection and underlying disease severity: insulin initiators generally had more advanced complications, whereas SGLT2i initiators tended to have fewer individual complications than GLP-1 initiators.” They concluded that the findings “were broadly reassuring regarding oncologic safety but did not support selecting glucose-lowering therapy for cancer prevention.” mdsc.pe/3WOm9aB
These patterns, the study authors wrote, “may reflect both treatment selection and underlying disease severity: insulin initiators generally had more advanced complications, whereas SGLT2i initiators tended to have fewer individual complications than GLP-1 initiators.” They concluded that the findings “were broadly reassuring regarding oncologic safety but did not support selecting glucose-lowering therapy for cancer prevention.” mdsc.pe/3WOm9aB
